Undervalued Valeant's Unique Strategy Is Underappreciated
This narrow-moat pharma firm's focus on acquiring already-approved products that aren't subject to reimbursement pressure is misunderstood.
This narrow-moat pharma firm's focus on acquiring already-approved products that aren't subject to reimbursement pressure is misunderstood.
David Krempa: Drug development is an inherently risky and uncertain business. Pharma companies have to invest capital today in drug discoveries that might pay off five to 10 years down the road if the drug is approved. Valeant (VRX) takes a unique strategy to pharmaceutical development. They focus on buying products that are already approved so that they can more accurately predict the returns on capital and they can ensure to shareholders that they are making value-creating investments.
The company also focuses their portfolio on cash pay products such as contact lenses, plastic-surgeon products, and over-the-counter medications. Because [these products] aren't covered by governments or large insurance companies, Valeant is isolated from some of the paying pressure that we are seeing a lot of the traditional pharmaceutical companies deal with right now.
Valeant's acquisition strategy creates a lot of skeptics, but we actually believe the company is a very rational buyer and we give management an Exemplary stewardship rating. They have shown they are willing to walk away when deal prices get too high, which we saw recently with Allergan (AGN), as well as a number of other times over the last six years. They have also shown a willingness to buy back their own shares when that represents the best investment. So, we don't have much concern that they are engaging in empire building and buying just to grow.
The company has also been a pioneer of the inversion strategy. They were one of the first pharma companies to do it back in 2010. Since then, we have seen the whole industry try to follow their lead and catch up to them, and we've seen almost a dozen pharmaceutical inversions over the last three years.
We think shares are currently undervalued, in part, due to some of the skepticism about their unique strategy, but we think long-term investors are going to get attractive returns on the stock.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.